Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
Unhelpful response received just now from HL
“We have checked our records and can confirm that we will unfortunately not be able to facilitate voting at the Novacyt meeting. The reason for this is because Novacyt is an overseas registered security. In order to be able to hold and trade overseas stocks, Hargreaves Lansdown holds the stocks as CREST Depository Interests (CDIs) as under UK law foreign stocks cannot be handled directly in CREST (the UK settlement system).
CDIs are issued by CREST, and one CDI is the equivalent of one share of an eligible foreign stock. Essentially, for each stock available as a CDI, CREST has the required number of shares held in its name (or the name of an intermediary acting for it) at the central securities depository in the company’s home country (these are the foreign equivalents of CREST – for example, DTCC in the US, Euroclear in much of Europe, Clearstream in Germany, SIS in Switzerland).
As the shares are not held in the name of Hargreaves Lansdown, we are unable to submit voting requests for overseas General Meetings as we will not appear on the register of shareholders. We apologise for this inconvenience.
If you have any other questions, please let us know.
Kind regards
Rebecca Chan
Corporate Actions”
Hi Kaeren & HereKittyKitty,
I couldn’t agree more with your latest posts. I have been saying the same for months and even wrote a “PR brief” spelling out what the company lacks in external marketing skills and a list of the key objectives that they could use to judge a PR agency with if they accepted they lack the know how to do it internally.
Pierre know
Merçi pour vos messages. Nous manquons içi les opinions de nos actionnaires françaises.
Puis-je pôser une question? Pourquoi les ventes de Novacyt sont-elles si mauvaises en France?
Aussi, que pensez-vous Novacyt faudra faire pour méliorer sa notoriété en France?
Thank you for your post. We miss the views of our French shareholders here. Can I as you a question? Why are Novacyt sales in France so poor? Also what do you think Novacyt should do to improve it’s awareness in France?
Merçi
Thanks Wilson fir those updated figures. They just reinforce my point that the BoD don’t seem to understand how maintaining a steady trickle of information to the media can help to support the SP and awareness of what’s going on. It doesn’t have to give away commercially valuable secrets.
PeterBuc, A good first post and I agree with your opening remark entirely. For what it’s worth I sent the following feedback today:
Presentation didn't address three topics properly: (A) Why the company is so undervalued against its peers (even allowing for the DHSC dispute). (B) The absence of PR and an apparent lack of understanding of its use in maintaining interest and value in a company's shares. And before you answer DHSC dispute again and importance of maintaining secrecy from competitors, there are over 130 distributors now and contracts received all over the world - none of which have been announced to help maintain interest in Novacyt and its shares. (C) Why is the company completely failing to do business in France when it is listed on the Bourse?
Is there any news about resolving the DHSC dispute? A response was promised no later than today: Dear Department of Health and Social Care,
“What stage are you currently at regarding the dispute with Novacyt and when can it be expected to be resolved?
Yours faithfully,
Mr Walsh”
Currently waiting for a response from Department of Health and Social Care, they should respond promptly and normally no later than 11 August 2021 (details).
Dear MrsKOB
You say “ If lateral flow tests are being used to allow schools, colleges, universities and other work places to reopen safely then surely they should be sufficient for the travel industry too?”
The answer is NO. Why do you think most other countries insist on PCR tests before entry?
I have posted this link https://www.statnews.com/2021/06/10/fda-accuses-company-of-distributing-unapproved-covid-test-using-falsified-data/ to health editor at D.Telegraph, Sky News & Science Editor at Sky asking why UK media aren’t reporting it. Let’s see ….
KilkennyTed: Well discovered. But why doesn’t Novacyt tell people about these international distributors? It seems odd that they don’t seize chances to make positive announcements when the opportunity is staring them in the face.
Pant wetter or not, in my opinion the share price will remain at these absurdly low levels until the company starts to talk regularly about its sales successes and tries to convince the market that there are prospects of them continuing in the future. It’s called basic Public Relations.
The world is a big place and at least half our revenue comes from somewhere other than the UK.
NCYT need to put the DHSC fiasco to one side for now and focus on the positives elsewhere to restore a realistic sp.
Well said John2015. It’s time Novacyt started to speak positively and regularly about what they are doing worldwide. That’s if they ARE selling anything.
Wesaid
Waffle is not Good PR neither is it exciting.
If you have a chance to pitch Warren Buffet in a lift and you come out with a repeat of your previous waffle then you can hardly be surprised that nobody is interested.
Yesterday a company that won a contract in the USA made a simple announcement confirming it in a positive way & their share price went up:https://www.share-talk.com/genedrive-plc-gdr-l-first-us-shipments-of-genedrive-96-sars-cov-2-kit/#gs.tujuji
Novacyt claims to have customers in 130 countries but they seem unable to make a single positive statement about their efforts. That’s at least 130 opportunities missed.